Targeting CFTR restoring aggrephagy to suppress HSC activation and alleviate liver fibrosis
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2024.113754 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Lu Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001 China. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Hepatic Stellate Cells, Liver Cirrhosis, Mice, Inbred C57BL. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND AND AIMS: Multiple studies have shown that hepatic fibrosis, a progressive condition that represents the endpoint of various chronic liver diseases, is primarily marked by the extensive activation of hepatic stellate cells (HSCs). However, the exact impact of cystic fibrosis transmembrane conductance regulator (CFTR) on HSCs during the development of hepatic fibrosis remains unclear. METHODS: In our study, we measured CFTR levels in tissue samples and in HSCs activated by TGF-β stimulation. We established mouse models of liver fibrosis using carbon tetrachloride (CCl4) and bile duct ligation (BDL). In vitro, we investigated the specific mechanisms of CFTR action in HSCs by exploring aggrephagy. We employed co-immunoprecipitation (co-IP) experiments to identify potential downstream targets of CFTR. Finally, through rescue experiments, we examined the impact of GTPase-activating protein - binding protein 1 (G3BP1) on CFTR-mediated activation of hepatic stellate cells. RESULT: In activated HSCs induced by TGF-β, the reduction of CFTR, various liver fibrosis models, and fibrotic tissue samples were identified. In vitro functional experiments confirmed that CFTR promoted the expression of fibrosis-related markers and aggrephagy in HSCs. Mechanistically, we found that CFTR directly interacts with G3BP1, thereby further promoting the TGF-β/Smad2/3 pathway. The inhibition of G3BP1 caused by CFTR knockdown reduced extracellular matrix deposition, contributing to alleviating liver fibrosis. CONCLUSION: We emphasize that CFTR activates aggrephagy and promotes HSC activation and hepatic fibrosis by targeting G3BP1, participating in the TGF-β/Smad2/3 signaling pathway. Overall, CFTR has been identified as a potential therapeutic target for liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001 China.
- Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001 China.
- Department of Gastroenterology, Tongzhou District Traditional Chinese Medicine Hospital, Nantong, China.
- Department Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001 China. Electronic address: 340190751@qq.com.
- Department Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001 China. Electronic address: lch670608@sina.com.
Zitieren
APA
Zhang, L., Huang, W., Ma, T., Shi, X., Chen, J., Hu, Y. L., Liu, Y. X., Liu, Z. X., & Lu, C. H. (2025). Targeting CFTR restoring aggrephagy to suppress HSC activation and alleviate liver fibrosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113754
Vancouver
Zhang L, Huang W, Ma T, Shi X, Chen J, Hu YL, et al. Targeting CFTR restoring aggrephagy to suppress HSC activation and alleviate liver fibrosis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113754
BibTeX
@article{Zhang2025,
author = {Zhang, Lu and Huang, Wei and Ma, Tao and Shi, Xiang and Chen, Jing and Hu, Yi-Lin and Liu, Yong-Xia and Liu, Zhao-Xiu and Lu, Cui-Hua},
title = {Targeting CFTR restoring aggrephagy to suppress HSC activation and alleviate liver fibrosis},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2024.113754}
}
EUVIMED